Stryker experienced strong quarterly growth with organic sales increasing by 9.3%. This growth was driven by double-digit growth in various businesses, including Neurovascular, Mako, and emergency care. Despite COVID-19 challenges, international organic growth outpaced the U.S., with strong results in regions like South Pacific and Western Europe. The integration of Wright Medical is progressing smoothly, and the company has raised its full-year organic sales guidance to 9-10%. Adjusted earnings per share are now projected to be in the range of $9.25 to $9.40, while the company expects unfavorable price reductions to remain at approximately 1%. Foreign currency exchange rates are expected to positively impact earnings per share by $0.10 for the full year.